Tourmaline Bio, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Tourmaline Bio, Inc. has completed its merger with Novartis AG, with shares acquired at $48.00 per share and delisting from Nasdaq initiated.
Tourmaline Bio, Inc. has amended its Executive Severance and Change in Control Plan, increasing benefits for its CFO and CBO/General Counsel in the event of a covered termination during a change in control period.
Novartis AG will acquire Tourmaline Bio, Inc. for $48.00 per share in cash, totaling approximately $1.4 billion, representing a significant premium for shareholders.
Tourmaline Bio announced positive topline results from its Phase 2 TRANQUILITY trial for pacibekitug and reported a cash runway into the second half of 2027.
Tourmaline Bio, Inc. reported positive topline data from its Phase 2 TRANQUILITY trial for pacibekitug in cardiovascular inflammation, demonstrating deep and sustained hs-CRP reductions with a favorable safety profile, while also outlining its strategic path forward for multiple indications.
Tourmaline Bio, Inc. announced the successful election of Dr. Caley Castelein and Aaron Kantoff as Class I directors and the ratification of Deloitte & Touche LLP as its independent auditor at its 2025 annual meeting of stockholders.
Tourmaline Bio reports positive topline results from its Phase 2 TRANQUILITY trial, demonstrating significant hs-CRP reductions with pacibekitug in patients with elevated hs-CRP and chronic kidney disease, supporting further development in cardiovascular diseases.
Tourmaline Bio announces its Q1 2025 financial results and highlights the ongoing Phase 2 TRANQUILITY trial for pacibekitug, expected to report topline data in Q2 2025.
Tourmaline Bio announces over-enrollment in its Phase 2 TRANQUILITY trial, strengthened Cardiovascular Scientific Advisory Board, and a strong cash position of $294.9 million as of December 31, 2024.
Tourmaline Bio released an updated corporate presentation detailing progress in their clinical trials for pacibekitug, a potential best-in-class anti-IL-6 monoclonal antibody.
Tourmaline Bio announced the over-enrollment of its Phase 2 TRANQUILITY trial, expansion of its Cardiovascular Scientific Advisory Board, and the nomination of a new indication for its lead drug, pacibekitug, at its Investor Day.
Tourmaline Bio announced its Q3 2024 financial results, highlighted by a strong cash position and progress in its clinical trials for pacibekitug.
Tourmaline Bio's Chief Medical Officer, Dr. Yung Chyung, has resigned effective October 31, 2024, to pursue another opportunity.
Tourmaline Bio has amended its bylaws to update advance notice provisions for stockholder nominations and reflect universal proxy rules.
Tourmaline Bio is progressing its pacibekitug antibody through late-stage clinical trials, targeting both FcRn+ and cardiovascular inflammation pathways.
Tourmaline Bio reported its second quarter 2024 financial results, highlighted by the first patient dosed in a Phase 2 trial and progress in its Thyroid Eye Disease program.
Tourmaline Bio has promoted Ryan Robinson to Chief Financial Officer and Treasurer, effective June 25, 2024.
Tourmaline Bio successfully held its 2024 annual meeting, electing two Class III directors and ratifying its independent auditor for the fiscal year ending December 31, 2024.
Tourmaline Bio reported its first quarter 2024 financial results, highlighted by the initiation of a Phase 2 trial and expansion of its Thyroid Eye Disease clinical program.
Tourmaline Bio announced its 2023 financial results and highlighted clinical advancements, including progress in trials for Thyroid Eye Disease and Atherosclerotic Cardiovascular Disease.
Tourmaline Bio has entered into an underwriting agreement for a public offering of common stock, expected to generate approximately $172.5 million in gross proceeds.
Tourmaline Bio has announced the commencement of an underwritten public offering of its common stock and provided an estimate of $203 million in total unrestricted cash and investments as of December 31, 2023.